BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 14, 2015
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iclaprim regulatory update

FDA granted Fast Track designation to IV iclaprim from Motif Bio to treat acute bacterial skin and skin structure infections (ABSSSIs) and hospital-acquired bacterial pneumonia (HABP). This half, Motif plans to start Phase III trials of iclaprim...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >